[1] Yakar T, Demir M, Dogan O, et al. High Dose Oral Furosemide with Salt Ingestion in the Treatment of Refractory Ascites of Liver Cirrhosis. Clin Invest Med, 2016, 39:27502.
[2] 邵晶, 张磊, 韩国宏, 等. 肝硬化顽固性腹水的治疗现状. 中华肝脏病杂志, 2016, 24:721-723.
[3] 赵林华, 尚建中. 卡维地洛降低乙型肝炎肝硬化患者肝静脉压力梯度的效果及影响因素分析. 肝脏, 2018, 23:326-329.
[4] 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2010年版). 中华内科杂志, 2011, 3:1-12.
[5] Ganesh K S, Majumdar A, Pavithra G. Quality of Life (QOL) and Its Associated Factors Using WHOQOL-BREF Among Elderly in Urban Puducherry, India. J Clin Diagn Res, 2014, 8:54-57.
[6] 李晶, 孙东杰, 王广川, 等. 卡维地洛与普萘洛尔降低肝硬化门静脉高压患者肝静脉压力梯度效果的对比分析. 临床肝胆病杂志, 2016, 32:114-118.
[7] 李红艳, 王果, 王壮, 等. 卡维地洛的使用与肝硬化腹水患者生存改善的相关性. 实用医学杂志, 2017, 33:129-132.
[8] Sinha R, Lockman KA, Mallawaarachchi N, et al. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol, 2017, 67:40-47.
[9] 刘亮. 卡维地洛和普萘洛尔对肝硬化胃底静脉曲张HVPG的影响. 肝脏, 2016, 21:758-760.
[10] Li T, Ke W, Sun P, et al. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open, 2016, 6:e010902.
[11] Franchis R D. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol, 2015, 63:743-752.
[12] Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol, 2017, 66:849-859.
[13] 李会贤, 孔德润. 卡维地洛在肝硬化门静脉高压患者中的临床应用. 国际消化病杂志, 2018, 38:102-105.
[14] Njei B, Mccarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut, 2016, 65:1393-1394. |
